Saturday, June 20, 2026

Search
HomeBusiness NewsPrecision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Business News

Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline

0
0
- Advertisement -

DURHAM, N.C.–()–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced program updates across its allogeneic CAR T cell…



Click here to view the original article.

- Advertisment -
Previous article
LUCID ALERT: Bragar Eagel & Squire, P.C. is Investigating Lucid Group, Inc. on Behalf of Lucid Stock…
Next article
The Global Institute for Disease Elimination awards USD1 million to ground-breaking health projects …

RELATED ARTICLES

- Advertisement -

Recently Viewed

Load more

FEATURED

POPULAR POSTS

POPULAR CATEGORY

The Australian Online News Network acknowledges the traditional custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.

FOLLOW US

© 2024 Australian Online News | Privacy Policy